Developer docs
API playgroundTry for free, no card

Search company profiles

InveniAI

Full company profile

uuid00098kk

Namestring
InveniAI
Legal namestring
InveniAI LLC
Websiteurl
inveniai.com
Company typeenum
Private
Founded yearint
2017
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersGuilford, United States
HQ citystring
Guilford
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI drug discovery, pharmaceutical AI platform, drug target identification, generative AI biotech, machine learning pharma
Industry4 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
AI Drug Discovery Platform
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Strategic Collaborations with Pharma
TypeLicensing Royalties
Description

InveniAI enters multi-year strategic collaborations with pharmaceutical companies where they receive upfront payments, development milestones, and royalties. Collaborations typically grant partners access to AlphaMeld platform for target discovery and drug development.

inveniai.com
2Milestone Payments
TypeLicensing Royalties
Description

Revenue generated through development and commercial milestones tied to progress of partnered drug candidates through clinical development phases.

inveniai.com
3Royalty Payments
TypeLicensing Royalties
Description

Ongoing royalties from successful commercialization of drug candidates identified or developed through the AlphaMeld platform for partners.

inveniai.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 4 records shown
1AlphaMeld
Description

AI-based universal signal detection platform powered by machine learning that accelerates innovation by identifying alpha signals for targets, drugs, and healthcare products and technologies. Primed with curated datasets for over a decade, it generates testable hypotheses across pharmacotherapy modalities including antibody, protein replacement, siRNA, mRNA, small molecule, cell and gene therapy, and gene-editing modalities.

inveniai.com
+3 more records
Core offering1 text field

InveniAI develops and licenses the AlphaMeld AI platform, a machine-learning-based universal signal detection system that identifies novel drug targets, drug candidates, and healthcare innovations from over a decade of curated scientific, medical, chemical, and biological data. The company partners with pharmaceutical and biotech firms through multi-year strategic collaborations that generate upfront payments, development milestones, and royalties, while also advancing its own therapeutic pipeline targeting the gut-brain axis and inflammasome pathways.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Reduces innovation cycle by 4-5 years according to GSK partnership
+3 more records
Product overview1 text field

InveniAI offers a unified platform-plus-modules architecture built around AlphaMeld®, an AI- and ML-powered platform that monitors drug targets, drugs, and healthcare products and technologies. The platform integrates complex scientific, medical, chemical, and biological data to identify transformative therapeutic opportunities. The product portfolio includes the core AlphaMeld® platform, the generative AI assistant ChatAlphaMeld™ for enhanced research capabilities, and specialized modules TargetMeld™ and RxMeld™ for predictive analytics in target and drug discovery. The company leverages this technology to accelerate drug discovery programs for industry partners and advance its own therapeutic pipeline targeting gut-brain axis and inflammasome pathways for chronic inflammatory diseases.

Product and service4 records
1AlphaMeld
CategoryAI Drug Discovery Platform
Description

AI-based universal signal detection system powered by machine learning that accelerates innovation by identifying alpha signals for targets, drugs, and healthcare products and technologies. Primed with over a decade of curated data sets, it generates testable hypotheses across pharmacotherapy modalities including antibody, protein replacement, siRNA, mRNA, small molecule, cell and gene therapy, and gene-editing modalities. Licensed to pharmaceutical and biotech partners through multi-year strategic collaborations.

2ChatAlphaMeld
CategoryGenerative AI Drug Discovery Assistant
Description

Generative AI Drug Discovery Assistant built on the AlphaMeld platform that integrates GPT-4, Turbo, Mixtral, Zephyr, and fine-tuned models. Provides enhanced natural language processing for rapid literature review, predictive analytics to inform clinical trial design, and AlphaMeld Knowledge Graph validation for cross-domain hypothesis verification.

3TargetMeld
CategoryAI Drug Discovery Module
Description

Predictive analytics product powered by AlphaMeld that provides comprehensive access to emerging targets for drug discovery and development.

4RxMeld
CategoryAI Drug Discovery Module
Description

Predictive analytics product powered by AlphaMeld that provides comprehensive access to emerging drug candidates and therapeutic development insights.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
1Ono Pharma
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-02-19
Description

AI-driven Target Discovery collaboration using AlphaMeld platform.

inveniai.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-07-20
Description

PRISM achieved milestone by generating INVA8003, a peptidomimetic inhibitor of PYCARD - successful generation of small molecule therapeutic candidate.

3Sosei Heptares
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-07-06
Description

Multi-target AI-powered collaboration to create transformative therapeutics for immune diseases. Combines InveniAI's validated AI-based platform with Sosei Heptares' GPCR structure-based drug design capabilities.

inveniai.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-04-27
Description

Multi-year multi-target drug discovery collaboration. InveniAI uses AlphaMeld to research and validate targets; Shionogi synthesizes and develops compounds for identified targets and advances select programs into research and clinical development. InveniAI eligible for up to $200 million per program for upfront payments, milestones, and royalties.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-12-09
Description

Expanded collaboration (from initial 2018 partnership) leveraging AlphaMeld for novel target discovery and validation to generate a clinical pipeline of therapeutic antibodies. Kyowa Kirin selects multiple programs to advance into clinical development. InveniAI receives upfront payment, development and commercial milestones, and royalties.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-09-09
Description

Collaboration for development of therapeutic candidates for gut-related diseases impacted by Gut-Brain Axis and inflammasome activation pathways. InveniAI uses AlphaMeld to identify and validate novel targets; PRISM BioLab designs small-molecule candidates against validated targets using their proprietary platform. PRISM eligible for upfront payments, development milestones, and single-digit royalties.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-07-29
Description

Three-year strategic collaboration leveraging AlphaMeld platform to capture consumer-specific innovation for GSK's internal and external R&D. The collaboration grants full access to InveniAI's AI Innovation Lab including the Consumer Healthcare Module of AlphaMeld and cross-functional expert teams. AI and ML have helped create efficiencies that shave 4-5 years off the innovation cycle.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-06-02
Description

Strategic partnership where TB Alliance leverages AlphaMeld platform for tuberculosis drug discovery and development.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

AI-driven small molecule discovery company using structure-based deep learning models across multiple therapeutic areas; competes with AlphaMeld's small-molecule modality support.

TypeDirect peer
Description

Public AI-driven drug discovery company combining high-throughput biology with machine learning to identify targets and advance therapeutic programs, directly comparable to InveniAI's AlphaMeld platform model.

TypeDirect peer
Description

AI-focused pharma company partnering with major pharma on target identification, molecule design, and clinical translation; operates a similar partner-led, milestone/royalty revenue model as InveniAI.

TypeDirect peer
Description

Machine learning-driven drug discovery company combining data generation and predictive models to advance therapeutic candidates, with analogous big-pharma collaboration structures to InveniAI.

TypeDirect peer
Description

AI-driven drug discovery company using knowledge graphs and ML to identify novel targets and indications; competes directly with InveniAI for pharma partnerships and target ID mandates.

TypeBroad incumbent
Description

Established computational chemistry and molecular simulation platform serving pharma R&D at scale; broader incumbent with overlapping drug-discovery AI capabilities versus InveniAI's narrower AI target-ID focus.

TypeDirect peer
Description

Public clinical-stage biopharma spun out of the same parent (BioXcel LLC) that incubated InveniAI; uses AI in drug re-innovation and is the company behind BXCL501, the Phase III AI-validated asset referenced by InveniAI.

TypeEmerging player
Description

Early-stage AI drug discovery company combining physics-based modeling with foundation models for chemistry; emerging direct competitor in the AI-led pharma partnership space.

TypeEmerging player
Description

AI biotech applying ML to patient-derived data for target discovery and clinical development across pharma; overlapping positioning with InveniAI's pharma-partnered, AI-first discovery approach.

10Tempus Labs
TypeBroad incumbent
Description

Large AI-enabled precision medicine company aggregating multi-modal clinical and molecular data for pharma partners; broader incumbent with adjacent AI-for-drug-development capabilities.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

InveniAI

AI Drug Discovery Platforminveniai.com

InveniAI firmographics

Firmographics
Name
InveniAI
Legal name
InveniAI LLC
Website
https://inveniai.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

InveniAI industry classification

Industry
Product category
AI Drug Discovery Platform
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • AI drug discovery
  • Pharmaceutical AI platform
  • Drug target identification
  • Generative AI biotech
  • Machine learning pharma

Where InveniAI is headquartered

Location

Headquarters

HQ city
Guilford
HQ country
United States
HQ region
North America

Offices2 records

Markets served

InveniAI business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Strategic Collaborations with Pharma: InveniAI enters multi-year strategic collaborations with pharmaceutical companies where they receive upfront payments, development milestones, and royalties. Collaborations typically grant partners access to AlphaMeld platform for target discovery and drug development.
  2. Milestone Payments: Revenue generated through development and commercial milestones tied to progress of partnered drug candidates through clinical development phases.
  3. Royalty Payments: Ongoing royalties from successful commercialization of drug candidates identified or developed through the AlphaMeld platform for partners.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

InveniAI product offering

Product offering

Core offering

InveniAI develops and licenses the AlphaMeld AI platform, a machine-learning-based universal signal detection system that identifies novel drug targets, drug candidates, and healthcare innovations from over a decade of curated scientific, medical, chemical, and biological data. The company partners with pharmaceutical and biotech firms through multi-year strategic collaborations that generate upfront payments, development milestones, and royalties, while also advancing its own therapeutic pipeline targeting the gut-brain axis and inflammasome pathways.

Product overview

InveniAI offers a unified platform-plus-modules architecture built around AlphaMeld®, an AI- and ML-powered platform that monitors drug targets, drugs, and healthcare products and technologies. The platform integrates complex scientific, medical, chemical, and biological data to identify transformative therapeutic opportunities. The product portfolio includes the core AlphaMeld® platform, the generative AI assistant ChatAlphaMeld™ for enhanced research capabilities, and specialized modules TargetMeld™ and RxMeld™ for predictive analytics in target and drug discovery. The company leverages this technology to accelerate drug discovery programs for industry partners and advance its own therapeutic pipeline targeting gut-brain axis and inflammasome pathways for chronic inflammatory diseases.

Differentiator

Problem solved

Functional benefit

Brands

  • AlphaMeld: AI-based universal signal detection platform powered by machine learning that accelerates innovation by identifying alpha signals for targets, drugs, and healthcare products and technologies. Primed with curated datasets for over a decade, it generates testable hypotheses across pharmacotherapy modalities including antibody, protein replacement, siRNA, mRNA, small molecule, cell and gene therapy, and gene-editing modalities.
  • ChatAlphaMeld
  • TargetMeld
  • RxMeld

Products and services

  • AlphaMeld AI-based universal signal detection system powered by machine learning that accelerates innovation by identifying alpha signals for targets, drugs, and healthcare products and technologies. Primed with over a decade of curated data sets, it generates testable hypotheses across pharmacotherapy modalities including antibody, protein replacement, siRNA, mRNA, small molecule, cell and gene therapy, and gene-editing modalities. Licensed to pharmaceutical and biotech partners through multi-year strategic collaborations.
  • ChatAlphaMeld Generative AI Drug Discovery Assistant built on the AlphaMeld platform that integrates GPT-4, Turbo, Mixtral, Zephyr, and fine-tuned models. Provides enhanced natural language processing for rapid literature review, predictive analytics to inform clinical trial design, and AlphaMeld Knowledge Graph validation for cross-domain hypothesis verification.
  • TargetMeld Predictive analytics product powered by AlphaMeld that provides comprehensive access to emerging targets for drug discovery and development.
  • RxMeld Predictive analytics product powered by AlphaMeld that provides comprehensive access to emerging drug candidates and therapeutic development insights.

Quantifiable outcome

  • Reduces innovation cycle by 4-5 years according to GSK partnership
  • +3 more outcomes

Companies that use InveniAI

Customer profile

Named customers7 records

Segments4 records

Ideal customer profiles3 records

InveniAI technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature4 records

InveniAI partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered minor and core.

  • Ono PharmaminorStrategic or Co-development Partner · 19 February 2024AI-driven Target Discovery collaboration using AlphaMeld platform.
  • PRISM BioLab (Milestone)coreStrategic or Co-development Partner · 20 July 2021PRISM achieved milestone by generating INVA8003, a peptidomimetic inhibitor of PYCARD - successful generation of small molecule therapeutic candidate.
  • Sosei HeptarescoreStrategic or Co-development Partner · 6 July 2021Multi-target AI-powered collaboration to create transformative therapeutics for immune diseases. Combines InveniAI's validated AI-based platform with Sosei Heptares' GPCR structure-based drug design capabilities.
  • ShionogicoreStrategic or Co-development Partner · 27 April 2021Multi-year multi-target drug discovery collaboration. InveniAI uses AlphaMeld to research and validate targets; Shionogi synthesizes and develops compounds for identified targets and advances select programs into research and clinical development. InveniAI eligible for up to $200 million per program for upfront payments, milestones, and royalties.
  • Kyowa KirincoreStrategic or Co-development Partner · 9 December 2020Expanded collaboration (from initial 2018 partnership) leveraging AlphaMeld for novel target discovery and validation to generate a clinical pipeline of therapeutic antibodies. Kyowa Kirin selects multiple programs to advance into clinical development. InveniAI receives upfront payment, development and commercial milestones, and royalties.
  • PRISM BioLabcoreStrategic or Co-development Partner · 9 September 2020Collaboration for development of therapeutic candidates for gut-related diseases impacted by Gut-Brain Axis and inflammasome activation pathways. InveniAI uses AlphaMeld to identify and validate novel targets; PRISM BioLab designs small-molecule candidates against validated targets using their proprietary platform. PRISM eligible for upfront payments, development milestones, and single-digit royalties.
  • GlaxoSmithKline Consumer HealthcarecoreStrategic or Co-development Partner · 29 July 2020Three-year strategic collaboration leveraging AlphaMeld platform to capture consumer-specific innovation for GSK's internal and external R&D. The collaboration grants full access to InveniAI's AI Innovation Lab including the Consumer Healthcare Module of AlphaMeld and cross-functional expert teams. AI and ML have helped create efficiencies that shave 4-5 years off the innovation cycle.
  • TB AllianceminorStrategic or Co-development Partner · 2 June 2020Strategic partnership where TB Alliance leverages AlphaMeld platform for tuberculosis drug discovery and development.

Scale indicators5 records

Recent moves8 records

Expansion highlights5 records

InveniAI competitors and assessment

Company assessment

Direct peers

  • Atomwise: AI-driven small molecule discovery company using structure-based deep learning models across multiple therapeutic areas; competes with AlphaMeld's small-molecule modality support.
  • Recursion Pharmaceuticals: Public AI-driven drug discovery company combining high-throughput biology with machine learning to identify targets and advance therapeutic programs, directly comparable to InveniAI's AlphaMeld platform model.
  • Exscientia: AI-focused pharma company partnering with major pharma on target identification, molecule design, and clinical translation; operates a similar partner-led, milestone/royalty revenue model as InveniAI.
  • Insitro: Machine learning-driven drug discovery company combining data generation and predictive models to advance therapeutic candidates, with analogous big-pharma collaboration structures to InveniAI.
  • BenevolentAI: AI-driven drug discovery company using knowledge graphs and ML to identify novel targets and indications; competes directly with InveniAI for pharma partnerships and target ID mandates.
  • BioXcel Therapeutics: Public clinical-stage biopharma spun out of the same parent (BioXcel LLC) that incubated InveniAI; uses AI in drug re-innovation and is the company behind BXCL501, the Phase III AI-validated asset referenced by InveniAI.

Broad incumbents

  • Schrödinger: Established computational chemistry and molecular simulation platform serving pharma R&D at scale; broader incumbent with overlapping drug-discovery AI capabilities versus InveniAI's narrower AI target-ID focus.
  • Tempus Labs: Large AI-enabled precision medicine company aggregating multi-modal clinical and molecular data for pharma partners; broader incumbent with adjacent AI-for-drug-development capabilities.

Emerging players

  • Iambic: Early-stage AI drug discovery company combining physics-based modeling with foundation models for chemistry; emerging direct competitor in the AI-led pharma partnership space.
  • Owkin: AI biotech applying ML to patient-derived data for target discovery and clinical development across pharma; overlapping positioning with InveniAI's pharma-partnered, AI-first discovery approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

InveniAI social profiles

Digital presence

InveniAI financial estimates

Financial estimate

Revenue estimate

Valuation estimate

InveniAI leadership team

Management profile

Number of profiles

Profiles6 records

InveniAI subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

InveniAI funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

InveniAI M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about InveniAI

What does InveniAI do?

InveniAI develops and licenses the AlphaMeld AI platform, a machine-learning-based universal signal detection system that identifies novel drug targets, drug candidates, and healthcare innovations from over a decade of curated scientific, medical, chemical, and biological data. The company partners with pharmaceutical and biotech firms through multi-year strategic collaborations that generate upfront payments, development milestones, and royalties, while also advancing its own therapeutic pipeline targeting the gut-brain axis and inflammasome pathways.

Is InveniAI a public or private company?

InveniAI is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was InveniAI founded?

InveniAI was founded in 2017. It employs 1 to 10 people.

Where is InveniAI based?

InveniAI is headquartered in Guilford, United States, in the North America region.

How does InveniAI make money?

Three revenue lines are on record. Strategic Collaborations with Pharma is the primary driver. The others are milestone Payments and royalty Payments.

Who are InveniAI's main competitors?

Direct peers on record are Atomwise, Recursion Pharmaceuticals, Exscientia, Insitro, BenevolentAI and BioXcel Therapeutics. Broad incumbents are Schrödinger and Tempus Labs. Emerging players are Iambic and Owkin.

Does InveniAI have an API?

Yes. AlphaMeld platform is accessible via the AI Innovation Lab with internal team of cross-functional experts. Contact for access: alphameld@inveniai.com. ChatAlphaMeld is a Generative AI Drug Discovery Assistant that integrates sophisticated AI models such as GPT-4, Turbo, Mixtral, Zephyr, and fine-tuned models. No public API documentation or developer portal identified; access appears to be enterprise/partner-facing. Developer documentation is at alphameld.com/auth?action=login.

What industry is InveniAI in?

InveniAI's product category is AI Drug Discovery Platform. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TmcnetInveniAI Announces Collaboration with Ono Pharmaceutical for Target DiscoveryInveniAI announced a collaboration with Ono Pharmaceutical to use its AlphaMeld AI platform for target discovery. Ono will validate hypotheses for multiple therapeutic candidates and retain exclusive rights worldwide. The partnership aims to accelerate drug programs for unmet medical needs.GlobeNewswireInveniAI and Kyowa Kirin Announce Achievement of Milestone in Research CollaborationInveniAI and Kyowa Kirin announced the first milestone in their research collaboration, triggering a milestone payment received by InveniAI. The AI platform AlphaMeld detected early signals of association between targets and clinical utility, validated in preclinical proof-of-concept studies. The companies plan further studies and additional novel programs.GlobeNewswireInveniAI and Kyowa Kirin Expand AI-Driven Partnership to a Multi-Year Strategic Collaboration for the Discovery of Novel Targets and Treatments Across Therapeutic AreasInveniAI and Kyowa Kirin expanded their partnership into a multi-year agreement for AI-driven drug discovery, giving Kyowa Kirin access to InveniAI's AlphaMeld platform. InveniAI will receive a committed annual research fee and milestone payments and royalties from Kyowa Kirin.GlobeNewswireInveniAI Announces Successful Completion of Milestone in its Collaboration with PRISM BioLab Focused on Designing Novel Inflammasome-Targeted Therapeutic CandidatesInveniAI completed the first milestone in its collaboration with PRISM BioLab, generating INVA8003, a peptidomimetic inhibitor of PYCARD. The company will pay an undisclosed milestone to PRISM, and INVA8003 is set to enter IND enabling studies in 2022.GlobeNewswireSosei Heptares and InveniAI Enter a Multi-Target AI-Powered and GPCR-Focused Drug Discovery CollaborationSosei Heptares and InveniAI announced a collaboration to identify GPCR targets for immune diseases, combining InveniAI's AlphaMeld AI platform with Sosei's GPCR structure-based drug design. The partnership aims to generate novel compounds to improve responses to existing immunotherapies, targeting unmet medical needs.PR NewswireSosei Heptares and InveniAI Enter a Multi-target AI-powered and GPCR-focused Drug Discovery CollaborationSosei Heptares and InveniAI announced a new multi-target R&D collaboration focused on using AI and machine learning to identify new therapeutic targets for immune diseases by exploring G-protein coupled receptors (GPCRs). The partnership combines InveniAI's AlphaMeld AI-powered target discovery platform with Sosei Heptares' GPCR structure-based drug design capabilities to generate novel compounds that could improve responses to existing immunotherapies. The goal is to address disease indications with high unmet medical needs, leveraging GPCRs which represent approximately 30% of known drug targets.BioWorldShionogi bags agreement for Inveniai’s AI drug discovery platform AlphameldShionogi signed a multitarget drug discovery collaboration with Inveniai for its AI platform Alphameld. Inveniai can receive up to $200 million per program from up-front payments, milestones, and royalties.GlobeNewswireInveniAI and Shionogi Enter AI-Powered Multi-Target Drug Discovery CollaborationInveniAI and Shionogi announced a multi-target drug discovery collaboration using InveniAI's AlphaMeld platform. Shionogi will synthesize and develop compounds for targets identified by InveniAI, with InveniAI eligible for up to $200 million per program. The collaboration aims to reduce discovery times and advance candidates into clinical development.MpadvisorBiopharma Trend Article: Tech Providers or Biotechs: The Quest to Find an Optimal Business Model Continues for AI Drug Discovery Companies… – MP AdvisorsAn MP Advisors article examines how AI drug discovery start-ups are choosing between biotech and tech-provider business models, noting over 200 disclosed deals with 50+ pharma companies. It cites examples such as BERG, Atomwise, InSilico Medicine and InveniAI, and argues that investors will likely specialize in one model.AiThorityInveniAI and Kyowa Kirin Enter AI-Powered Novel Target Discovery CollaborationInveniAI and Kyowa Kirin expanded their collaboration to use InveniAI's AlphaMeld platform for novel target discovery and validation. Kyowa Kirin will select multiple programs to advance into clinical development, with InveniAI eligible for upfront payments, milestones, and royalties.